These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19862519)

  • 1. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):484-93. PubMed ID: 19862519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Jazbec T; Girod PP; Url C; Thomé C; Riechelmann H; Sprinzl GM; Fraedrich G; Virgolini IJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):94-99. PubMed ID: 30630744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
    Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
    Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
    Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using
    Jha A; Patel M; Carrasquillo JA; Ling A; Millo C; Saboury B; Chen CC; Wakim P; Gonzales MK; Meuter L; Knue M; Talvacchio S; Herscovitch P; Rivero JD; Chen AP; Nilubol N; Taïeb D; Lin FI; Civelek AC; Pacak K
    AJR Am J Roentgenol; 2022 Feb; 218(2):342-350. PubMed ID: 34431366
    [No Abstract]   [Full Text] [Related]  

  • 10. 18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma.
    Taïeb D; Jha A; Guerin C; Pang Y; Adams KT; Chen CC; Romanet P; Roche P; Essamet W; Ling A; Quezado MM; Castinetti F; Sebag F; Pacak K
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1574-1582. PubMed ID: 29534198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma.
    El-Rabadi K; Weber M; Mayerhofer M; Nakuz T; Scherer T; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
    Anticancer Res; 2016 Aug; 36(8):4187-93. PubMed ID: 27466530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
    Timmers HJ; Hadi M; Carrasquillo JA; Chen CC; Martiniova L; Whatley M; Ling A; Eisenhofer G; Adams KT; Pacak K
    J Nucl Med; 2007 Oct; 48(10):1599-606. PubMed ID: 17873132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A; Putzer D; Frech A; Decristoforo C; Uprimny C; Gasser RW; Shulkin BL; Url C; Widmann G; Prommegger R; Sprinzl GM; Fraedrich G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.
    Marzola MC; Chondrogiannis S; Grassetto G; Rampin L; Maffione AM; Ferretti A; Opocher G; Schiavi F; Colletti PM; Rubello D
    Clin Nucl Med; 2014 Jan; 39(1):e53-8. PubMed ID: 23856824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour.
    Fiebrich HB; de Jong JR; Kema IP; Koopmans KP; Sluiter W; Dierckx RA; Walenkamp AM; Links TP; Brouwers AH; de Vries EG
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1854-61. PubMed ID: 21698413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal tracer uptake by
    Noordzij W; Glaudemans AWJM; Schaafsma M; van der Horst-Schrivers ANA; Slart RHJA; van Beek AP; Kerstens MN
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1560-1566. PubMed ID: 31011769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison between [
    He Q; Zhang Z; Zhang L; Zhang B; Long Y; Zhang Y; Liao Z; Zha Z; Zhang X
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1989-2001. PubMed ID: 38300262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
    Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
    Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative
    Amodru V; Guerin C; Delcourt S; Romanet P; Loundou A; Viana B; Brue T; Castinetti F; Sebag F; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):278-282. PubMed ID: 28918451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.